Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Ipilimumab

4

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

1
Last update : 19/10/2014
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
CTLA4 blocking immunotherapy
3
Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx
5
Tremelimumab
1

Publications

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.
British journal of cancer 2016 May 10;114;1084-9 2016 May 10
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
The New England journal of medicine 2015 May 21;372;2006-17 2015 May 21
Severe acute respiratory distress syndrome due to ipilimumab.
The European respiratory journal 2013 Sep;42;866-8 2013 Sep
CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation.
Blood 2009 Feb 12;113;1581-8 2009 Feb 12

Powered by

  • ^
  • Contact
  • Cookies
  • About